Interpace Biosciences (IDXG) Announces 1-for-5 Reverse Stock Split

What Happened

• Interpace Biosciences, Inc. (IDXG) filed a Form 8-K reporting that its board approved and filed a Certificate of Amendment to effect a 1-for-5 reverse stock split of its common stock. The Certificate of Amendment was filed with Delaware on August 25, 2026, and the Reverse Stock Split becomes effective at 12:01 a.m. ET on August 27, 2026. The company also issued a press release on August 26, 2026 announcing the change.

Key Details

• Reverse split ratio: 1-for-5 (every five shares combined into one share); par value per share unchanged.
• Effective timing: 12:01 a.m. Eastern Time on August 27, 2026; trading on the OTCID will reflect the split at market open on Aug 27.
• Fractional shares: no fractional certificates will be issued; fractional results will be rounded up to the nearest whole share.
• Administrative changes: temporary ticker change to IDXGD for 20 trading days; new CUSIP 46062X 402; transfer agent is Equiniti Trust Company, LLC. Outstanding stock options and shares available under the company’s 2026 equity plans will be adjusted proportionately.

Why It Matters

• For investors, the reverse split reduces the number of outstanding shares and increases the per-share price proportionately; it does not change an investor’s proportional ownership or the company’s market value. The split may affect trading liquidity and how shares are quoted (temporary ticker change and new CUSIP). Option exercise prices and the number of shares under equity plans will be adjusted to reflect the split. Electronic and street-name holders do not need to take action; outstanding paper certificates will be exchanged automatically.